Patients with nontuberculous mycobacterial pulmonary disease caused by Mycobacterium avium complex had significantly improved survival if they achieved microbiological cure at the end of treatment, ...
A phase 3 trial evaluating a nebulized clofazimine inhalation suspension (MNKD-101) for the treatment of refractory nontuberculous mycobacterial (NTM) ...
Avian tuberculosis, also known as mycobacterium avium complex (MAC) or MAC lung disease, is a respiratory illness. It can lead to symptoms such as chronic cough, shortness of breath, and weight loss.
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious ...
Prominent Nontuberculous Mycobacterial (NTM) Infections emerging therapies include ALIS, Antimycobacterial regimen, ...
Blinded aggregate analysis of AN2 Therapeutics' ongoing Phase 2 study showed potentially lower-than-expected efficacy. The company continues to expect to announce topline data from the Phase 2 part of ...
MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for ...
Hoping to lighten its load, RedHill Biopharma has thrown a phase 3 lung disease program from its pack in an attempt to conserve resources and carry its COVID-19 med to the top. The Israel-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback